STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] BIOLARGO, INC. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

BioLargo, Inc. (BLGO) furnished an investor presentation under Item 7.01 (Regulation FD). The company plans to present the slide deck attached as Exhibit 99.1 during an investor webcast on November 14, 2025 at 1:30 PM Pacific Time.

The information is expressly stated as furnished, not filed, and is not subject to liability under Section 18 of the Exchange Act nor incorporated by reference into other filings. The company notes Safe Harbor language applies to forward-looking statements in the slides. Exhibits include 99.1 (slide deck) and 104 (Cover Page Inline XBRL).

Positive
  • None.
Negative
  • None.
false 0000880242 0000880242 2025-11-14 2025-11-14
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): November 14, 2025
 
BioLargo, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-19709
 
65-0159115
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
 
14921 Chestnut St., Westminster, California
 
92683
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (888) 400-2863
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
BLGO
OTCQX
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
Item 7.01 Regulation FD Disclosure.
 
BioLargo, Inc., intends to present the slides attached as Exhibit 99.1, which are incorporated herein by reference, on November 14, 2025, at 1:30 PM Pacific Time, at an investor webcast.
 
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the slide presentation attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading “Safe Harbor Act” in Exhibit 99.1 attached hereto.
 
Item 9.01. Financial Statements and Exhibits.
 
(d)         Exhibits.
 
   
Exhibit No.
Description
99.1
Slide deck presentation
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
                 
Date: November 14, 2025
     
BIOLARGO, INC.
         
           
By:
 
/s/ Dennis P. Calvert
               
Dennis P. Calvert
               
President and Chief Executive Officer
 
 

FAQ

What did BioLargo (BLGO) announce in this 8-K?

BioLargo furnished an investor slide presentation as Exhibit 99.1 under Item 7.01 (Reg FD).

When is BioLargo’s investor webcast?

The webcast is scheduled for November 14, 2025 at 1:30 PM Pacific Time.

Is the information considered filed with the SEC?

No. The information is furnished, not filed, and not subject to Section 18 liability or incorporation by reference.

Which exhibits accompany the 8-K for BLGO?

Exhibits are 99.1 (slide deck presentation) and 104 (Cover Page Inline XBRL data file).

Does BioLargo commit to updating the presentation information?

The company states it has no duty or obligation to update or revise the information, though it may do so.

What forward-looking statement guidance is provided?

The company references a Safe Harbor Act section in Exhibit 99.1 for forward-looking statements.
Biolargo

OTC:BLGO

BLGO Rankings

BLGO Latest News

BLGO Latest SEC Filings

BLGO Stock Data

71.07M
253.84M
13.8%
0.04%
Chemicals
Basic Materials
Link
United States
Westminster